Bristol's Abatacept Shows Elevated Infection Risk In Phase III Safety Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm presents safety, updated pivotal data at European League Against Rheumatism meeting. BLA submission for the first-in-class rheumatoid arthritis biologic was completed in March.